Key Takeaways
- A 100,000-person study found semaglutide users had a 44% lower risk of depression and 38% lower risk of anxiety disorders
- Psychiatric hospital visits and sick leave dropped by 42% while on the medication
- Substance use disorder-related hospital care fell by 47%
- Published in The Lancet Psychiatry (May 2026) — the largest study of its kind
- The mental health benefits may be partly independent of weight loss itself
Ozempic was designed to lower blood sugar and promote weight loss. Nobody expected it to also meaningfully reduce depression, anxiety, and substance use disorders. Yet that is precisely what one of the most comprehensive studies ever conducted on semaglutide has found. Published in The Lancet Psychiatry in May 2026, the findings are reshaping how clinicians and researchers think about this class of medications.
What the Study Found
Researchers from the University of Eastern Finland, Karolinska Institutet in Sweden, and Griffith University in Australia tracked nearly 100,000 people — including more than 20,000 taking GLP-1 medications — over 13 years using Swedish national health registers. They compared each person’s mental health outcomes during periods when they were taking semaglutide against periods when they were not.
The results were striking across every mental health category measured:
Mental Health Improvements on Semaglutide
Depression risk: 44% lower compared to periods off the medication. This is a larger effect than many dedicated antidepressants show in clinical trials.
Anxiety disorders: 38% reduction in risk. Participants had fewer anxiety-related hospital episodes and significantly less anxiety-related sick leave.
Psychiatric hospital care and sick leave: 42% drop overall. This represents a substantial reduction in the real-world burden of mental illness.
Substance use disorders: 47% lower hospital care and work absence. This aligns with emerging evidence that GLP-1 drugs reduce addictive behaviours including alcohol consumption.
Why Might Ozempic Improve Mental Health?
Researchers are careful to note the study cannot prove causation — it shows a very strong association. But several biological mechanisms are under investigation:
- Weight loss benefits. The psychological impact of significant weight loss is well documented — improved body image, increased mobility, and reduced chronic pain all contribute to better mental health outcomes.
- Better blood sugar control. Blood sugar fluctuations are known to affect mood. Stabilising blood sugar may independently reduce anxiety and depressive episodes.
- Direct brain effects. GLP-1 receptors exist throughout the brain, including in regions associated with mood regulation and reward processing. Dr. Markku Lahteenvuo noted the drug may act through direct neurobiological mechanisms affecting the brain’s reward system.
- Reduced inflammation. Semaglutide has anti-inflammatory properties. Chronic inflammation is strongly linked to depression, and reducing it may directly improve mood.
The Substance Use Finding
Perhaps the most unexpected result was the 47% reduction in substance use disorder-related care. Professor Mark Taylor commented: “Alcohol-related problems often have downstream effects on mood and anxiety, so we expected the effect to be positive on these as well.” But the magnitude of the reduction surprised even the research team.
Earlier, smaller studies had already suggested GLP-1 drugs reduce alcohol cravings. This large, long-term registry study adds substantial weight to what is now a consistent pattern across multiple data sources.
What This Means for Patients
For patients already taking semaglutide for diabetes or weight management, these findings are reassuring — the drug may be delivering mental health benefits alongside its primary effects. For clinicians, it raises the question of whether GLP-1 medications might eventually be considered as part of a broader psychiatric treatment toolkit, particularly for patients where metabolic and mental health conditions overlap.
For patients in India, where both type 2 diabetes and depression carry significant stigma and often go undiagnosed, this dual benefit is particularly noteworthy. A medication that addresses metabolic health while also reducing psychiatric burden could be transformative at a population level.
Supporting Mood and Mental Wellness Naturally
Whether or not you are a candidate for semaglutide, supporting your mental wellness through evidence-based natural means is always worthwhile. Ashwagandha KSM-66 is one of the best-studied adaptogens for stress, anxiety, and mood support — with multiple clinical trials showing meaningful reductions in perceived stress and cortisol levels.
Recommended: Ashwagandha KSM-66 for Stress and Mood Support
If you are managing stress, anxiety, or low mood, Ashwagandha KSM-66 is the most clinically studied form of ashwagandha — shown in trials to reduce cortisol levels and improve subjective wellbeing.
The Bottom Line
The data from 100,000 people over 13 years is hard to dismiss. Semaglutide users are significantly less likely to be hospitalised for depression, anxiety, or substance use while on the drug. The mechanisms are not fully understood yet, but the pattern is consistent and the effect sizes are large. If you are taking a GLP-1 medication, this is one more reason to stay the course under medical supervision — the benefits may extend well beyond the original prescription.
Medically reviewed by Dr. Ajit Jha, MBBS, MD Medicine | IMA Lifetime Member | Editorial Board Member, International Journal of Diabetes and Endocrinology (IJDE). This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medication.
📖 Related Articles